Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy

J Infect Dis. 2016 Mar 15;213(6):1008-12. doi: 10.1093/infdis/jiv521. Epub 2015 Nov 1.

Abstract

Long-term treatment with interferon (IFN) alfa plus ribavirin decreases the proviral human immunodeficiency virus type 1 (HIV) DNA level. However, the short-term impact of IFN alfa on persistent HIV and its effects on immune activation after antiretroviral therapy remain unknown. Our study showed that the cell-associated HIV RNA level and CD4(+) T-cell activation decreased in the IFN group (n = 10). No changes were detected in levels of residual plasma viremia, replication-competent reservoirs, proviral DNA, or 2-long-terminal repeat circles, although APOBEC3G, TRIM5α, BST2, and TRIM22 were upregulated in the IFN group. These data suggest that short-term treatment with IFN alfa combined with RBV decreases HIV expression, in part through inhibition of HIV transcription by TRIM22 and decrease in T-cell activation.

Keywords: CD4+ T-cell subpopulations; HIV RNA expression; HIV persistence; HIV/HCV coinfection; IFN alfa; Siglec-1; TRIM22; immune activation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Biomarkers
  • CD4-Positive T-Lymphocytes / classification
  • CD4-Positive T-Lymphocytes / drug effects*
  • CD4-Positive T-Lymphocytes / physiology
  • Coinfection
  • Female
  • Gene Expression Regulation, Viral / drug effects
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV-1 / physiology*
  • Hepacivirus
  • Hepatitis C / complications*
  • Humans
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Lymphocyte Activation / drug effects
  • Male
  • Middle Aged
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use
  • Ribavirin / administration & dosage
  • Ribavirin / therapeutic use

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • Biomarkers
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a